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Summary  Adverse  drug  reactions  are  a  significant  cause  of  morbidity  and  mortality  and  rep-
resent a  major  burden  on  the  healthcare  system.  Some  of  those  reactions  are  immunologically
mediated (hypersensitivity  reactions)  and  can  be  clinically  subdivided  into  two  categories:
immediate  reactions  (IgE-related)  and  delayed  reactions  (T-cell-mediated).  Delayed  hypersen-
sitivity reactions  include  both  systemic  syndromes  and  organ-specific  toxicities  and  can  be
triggered  by  a  wide  range  of  chemically  diverse  drugs.  Recent  studies  have  demonstrated
a strong  genetic  association  between  human  leukocyte  antigen  alleles  and  susceptibility  to
delayed drug  hypersensitivity.  Most  notable  examples  include  human  leukocyte  antigen  (HLA)-
B*57:01 allele  and  abacavir  hypersensitivity  syndrome  or  HLA-B*15:02  and  HLA-B*58:01  alleles
related  to  severe  cutaneous  reactions  induced  by  carbamazepine  and  allopurinol,  respectively.
This review  aims  to  explore  our  current  understanding  in  the  field  of  pharmacogenomics  of
HLA-associated  drug  hypersensitivities  and  its  translation  into  clinical  practice  for  predicting
adverse  drug  reactions.
© 2017  Société  française  de  pharmacologie  et  de  thérapeutique.  Published  by  Elsevier  MassonE
F
SAS. All  rights  reserved.
AbbreviationsADRs  adverse  drug  reactions
APC  antigen-presenting  cell
DIHS  drug-induced  hypersensitivity  syndrome
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DRs  hypersensitivity  drug  reactions
IV  human  immunodeficiency  virus
LA  human  leukocyte  antigen
PE  maculopapular  eruption
PV  negative  predictive  value
PV  positive  predictive  value
JS  Stevens-Johnson  syndrome
CR  T-cell  receptor



















































































































EN  toxic  epidermal  necrolysis
HO  World  Health  Organization
ypersensitivity drug reactions
dverse  drug  reactions  (ADRs)  are  defined  by  the  World
ealth  Organization  (WHO)  as  an  ‘‘unintended,  noxious
esponse  to  a  drug  that  occurs  at  a  dose  usually  prescribed
or  human  patients’’  [1].  ADRs  are  recognized  as  a  major
ealth  problem,  in  the  United  States  they  are  responsible
f  6—7%  of  hospitalization  cases  and  represent  the  fourth
o  sixth  leading  cause  of  death  accounting  for  100,000  fatal
ases  annually  [2].  In  Europe,  it  is  estimated  that  5%  of  all
ospital  admission  and  197,000  deaths  per  year  are  caused
y  ADRs  [3].  Along  with  the  mortality  and  morbidity  bur-
en,  it  is  estimated  that  the  total  cost  to  society  of  ADRs  is
 177  billion  and  D  79  billion  in  the  USA  and  Europe,  respec-
ively  [3,4].  Moreover,  ADRs  remain  a  huge  cost  burden  for
harmaceutical  industry  representing  the  main  cause  of  drug
ithdrawal  from  the  market  [5].
The  historical  pharmacologic  classification  of  ADRs  by
awlins  and  Thompson  classifies  these  into  two  main
ategories  [6].  Type  A  reactions  are  predictable,  dose-
ependent,  and  related  to  pharmacologic  properties  of  the
rug,  and  Type  B  reactions,  accounting  for  approximately
0%  of  all  ADRs,  are  unpredictable,  not  dose-dependent
nd  correspond  to  hypersensitivity  drug  reactions  (HDRs).
ccurring  only  in  susceptible  individuals  Type  B  ADRs  are
ometimes  termed  ‘‘idiosyncratic’’.  Since,  terminology  used
o  define  HDRs  is  often  confusing  due  to  a  lack  of  commonly
ccepted  definitions,  the  European  Academy  of  Allergology
nd  Clinical  Immunology  published  a  statement  paper  in
rder  to  standardize  the  nomenclature  of  allergic  diseases,
lso  including  drug  allergy  [7].  The  revised  nomenclature  has
een  further  adopted  by  the  World  Allergy  Organization  [8].
he  proposed  classification  define  as  ‘‘drug  allergy’’  those
DRs  in  which  immunologic  mechanisms  may  be  demon-
trated,  while  HDRs  with  symptoms  and  signs  similar  to
eal  allergies  but  not  triggered  by  a  specific  immunological
echanism  are  referred  to  as  ‘‘non-allergic  drug  hypersen-
itivity’’  (e.g.  non-specific  histamine  release,  arachidonic
cid  pathway  activation,  bradykinin  pathway  alteration,
tc.).  With  regard  to  the  onset  of  symptoms,  drug  allergies
ay  be  further  classified  as  immediate  or  delayed,  sug-
esting  also  the  immunological  mechanism  underlying  the
eaction  [7,8].
mmunological basis of hypersensitivity
rug reactions
mmediate  reactions  occur  immediately  after  drug  expo-
ure,  are  IgE-dependent,  and  derive  from  mast  cell  degranu-
ation  and  release  of  pro-inflammatory  mediators.  Clinical
anifestations  include  erythema,  urticaria,  angioedema,
ronchospasm,  and  anaphylactic  shock.  Delayed  hypersen-
itivity  reactions  generally  occur  days,  or  even  weeks,
fter  drug  exposure  and  are  mediated  by  antigen-specific lymphocytes.  Examples  of  delayed-type  HDRs  include
oth  systemic  syndromes  (e.g.  drug  rash  with  eosinophilia
nd  systemic  symptoms)  and  organ-specific  toxicities  (e.g.
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eactions  correspond  to  type  IV  hypersensitivity  according
o  the  classification  system  of  Gell  and  Coombs  [9].  Since
-cells  can  orchestrate  different  immune  responses  result-
ng  in  different  clinical  entities,  delayed  reactions  can  be
urther  classified  into  IVa  (Th1  cells),  IVb  (Th2  cells),  IVc
cytotoxic  T-cell),  and  IVd  (neutrophils)  [10].
Since  drugs  are  generally  too  small  to  stimulate  an
mmune  response  (molecular  weights  <  1000  Daltons),  sev-
ral,  non-mutually  exclusive,  models  have  been  proposed
o  explain  how  drugs  can  become  immunogenic  and  trigger
-cells:  the  ‘‘hapten/pro-hapten  model’’,  the  ‘‘Pi  (pharma-
ologic  interaction  with  immune  receptors)  concept’’,  the
‘altered  peptide  repertoire  hypothesis’’  and  the  ‘‘danger
ignal’’  theory.  The  ‘‘hapten/pro-hapten  model’’  proposes
hat  a  chemically  reactive  drug,  acting  as  hapten,  can
ind  covalently  to  self-proteins  (carriers)  creating  fully
ntigenic  complexes.  These  neo-antigens  are  processed  by
n  antigen-presenting  cell  (APC),  loaded  onto  the  HLA
olecules  and  then  presented  to  appropriate  T-cells.  The
ro-hapten  is  a  chemically  non-reactive  drug  that  becomes
eactive  upon  metabolism  [11].  According  to  ‘‘pi-concept
ypothesis’’,  a  chemically  inert  drug,  unable  to  covalently
ind  to  proteins,  is  able  to  structurally  ‘‘fit’’  into  the  T-
ell  receptor.  This  interaction  needs  neither  metabolism
or  antigen  processing.  The  initial  stimulation  of  the  T-
ell  receptor  (TCR)  is  further  supplemented  by  TCR-HLA
nteraction  and  probably  must  take  place  in  a  context  of
yper-reactive  T-cells  with  a  low  threshold  level  of  activa-
ion  [12—14].  The  ‘‘altered  peptide  repertoire  hypothesis’’
roposes  that  the  drug  binds  the  antigen-binding  groove  of
LA  thus  modifying  the  antigen-binding  cleft  thus  altering
he  repertoire  of  self-peptides  that  are  bound  and  pre-
ented.  Since  T-cells  are  educated  to  be  tolerant  to  a  specific
ool  of  peptides  during  thymic  maturation,  the  presenta-
ion  of  these  neo-self-peptides  may  induce  T-cell  activation.
ecent  observations  provide  strong  evidence  that  this  model
s  implicated  in  HDRs  related  to  abacavir  and  carbamazepine
15]. Last  hypothesis  proposes  that  the  drug  itself  or  conco-
itant  situations  (e.g.  viral  infections)  can  provide  ‘‘danger
ignals’’  capable  of  upregulating  costimulatory  molecules
nd  cytokines  in  innate  immune  cells,  thus  facilitating  the
mmune  activation  [11].
The  human  leukocyte  antigen  (HLA)  molecules  plays  a
rucial  role  in  T-cells  activation  by  presenting  processed
ntigens  to  the  T-cell  receptor  expressed  on  T  lympho-
ytes.  Broadly  speaking,  there  are  two  main  types  of  HLA
olecules:  the  HLA  class  I  molecules,  expressed  on  most
ucleated  cells,  and  the  HLA  class  II  molecules,  expressed
y  APCs,  such  as  monocytes  or  dendritic  cells.  HLA  class  I
olecules  are  encoded  by  three  loci  known  as  HLA-A,  HLA-
,  and  HLA-C;  HLA  class  II  molecules  are  encoded  by  three
oci  known  as  HLA-DR,  HLA-DQ,  and  HLA-DP.  HLA  class  I  and
lass  II  molecules  initiate  the  adaptive  immune  response  by
resenting  antigens  to  CD8+  (cytotoxic)  and  CD4+  (helper)
-cells.  Because  the  HLA  molecules  need  to  present  an  huge
ariety  of  ‘‘self’’  and  ‘‘non-self’’  peptides,  the  HLA  genes
re  both  numerous  and  extremely  polymorphic.  Taking  into
ccount  the  crucial  role  of  HLA  in  immune  response  it  is  not
urprising  that  particular  HLA  alleles  have  been  associated
ith  susceptibility  to  diseases  in  which  the  immune  system  is
onsidered  the  principal  mediator,  like  infectious  or  autoim-






















































Pharmacogenetics  of  hypersensitivity  drug  reactions  
have  been  associated  with  an  increased  risk  of  delayed  HDRs.
The  evidence  that  certain  HLA  alleles  may  increase  the  risk
of  HDRs  has  prompted  the  development  of  screening  test
strategies  and  labeling  changes  to  drug  information  sheets.
To  date,  the  best-characterized  HLA-HDRs  associations
include  abacavir,  carbamazepine,  and  allopurinol.
Specific examples of HLA-related
hypersensitivity drug reactions
Abacavir
Abacavir  is  a  nucleoside  analog  reverse-transcriptase
inhibitor  used  as  part  of  combination  therapy  for  the  treat-
ment  of  human  immunodeficiency  virus  (HIV)  infection.
Abacavir  is  generally  well  tolerated,  but  5—8%  of  patients
may  develop  an  hypersensitivity  reaction  generally  within
the  first  6  weeks  of  treatment  [18].  Abacavir  hypersen-
sitivity  reaction  is  clinically  characterized  by  fever,  rash,
constitutional,  gastrointestinal  and  respiratory  symptoms.
Symptoms  worsen  with  the  continuation  of  abacavir  and
can  be  life-threatening  if  the  drug  is  re-administered  after
discontinuation  [19].  Even  if  Abacavir  hypersensitivity  was
reported  in  the  pre-marketing  phase  of  its  development,
only  in  2002,  two  independent  groups  described  a  strong
association  between  the  HLA-B*57:01  allele  and  susceptibil-
ity  to  develop  abacavir  hypersensitivity  syndrome  [20,21].
This  association  was  successively  reported  by  different
groups  [22—25],  but  it  was  definitively  confirmed  in  2008
with  the  results  of  the  largest  randomized  clinical  trial  per-
formed  to  date  in  pharmacogenetics:  the  PREDICT-1  trial.
In  this  study,  1956  patients  from  19  countries  were  ran-
domized  to  either  HLA-B*5701  genetic  screening  (carriers
of  HLA-B*5701  did  not  receive  abacavir)  or  to  the  standard
of  care  (no  screening  and  all  patients  received  abacavir).
Genetic  screening  virtually  eliminated  all  immunologically
confirmed  HDRs  (0%  in  the  screened  group  versus  2.7%  in
the  control  group),  thus  supporting  a  great  translational
potential  of  HLA-B*57:01  as  screening  test  for  abacavir-
related  HDR  [26].  Nevertheless,  the  generalisability  of  the
PREDICT-1  results  to  all  races  was  limited  by  its  prevalent
Caucasian  population  (84%  of  the  enrolled  patients  were
Caucasian).  The  SHAPE  trial,  a  case-control  study  including
similar  percentages  of  black  and  white  patients,  revealed  a
100%  negative  predictive  value  (NPV)  of  HLA-B*57:01  test-
ing  for  abacavir  hypersensitivity  both  for  black  and  white
patients,  thus  confirming  the  value  of  the  screening  across
different  ethnicities  [27].  A  recent  meta-analysis  further
confirmed  that  HLA-B*57:01  carriage  is  significantly  asso-
ciated  with  abacavir-induced  hypersensitivity  reactions  in
Whites,  Blacks,  and  Hispanics  [28].  The  NPV  of  HLA-B*57:01
screening  is  100%  (which  means  that  HLA-B*57:01  negative
individuals  will  not  develop  hypersensitivity)  making  this
test  highly  valuable  in  predicting  the  risk  of  abacavir-related
HDR.  Nevertheless,  the  positive  predictive  value  (PPV)  of
HLA-B*57:01  genetic  testing  is  estimated  to  be  around  50%
implying  that  around  half  of  all  patients  found  positive  at
screening  actually  will  develop  the  HDR  if  exposed  to  aba-
cavir.  High  NPV  and  low  PPV  seems  to  be  a  characteristic






hat  these  markers  are  necessary  but  not  sufficient  for  ADR
nset,  and  other  genes  and/or  environmental  factors  should
e  involved.
Interestingly,  HLA-B*57:01  has  also  been  associated  to
n  increased  risk  of  drug-induced  liver  injury  in  patients
reated  with  the  antibiotic  flucloxacillin  [34].  The  associ-
tion  of  HLA-B*57:01  with  both  abacavir  hypersensitivity
nd  flucloxacillin-induced  hepatotoxicity  indicates  that  the
ame  HLA  allele  lead  to  completely  different  reactions
riggered  by  chemically  unrelated  drugs.  In  addition,  HLA-
*57:01  has  been  associated  with  slow  or  non-progression  of
IV  infection  [35—37]. Taken  together,  these  data  seem  to
uggest  that  HLA-B*57:01  is  related  with  an  ‘‘hyperactive’’
mmune  response  that,  on  one  hand  may  increase  the  risk  to
evelop  hypersensitivity  reactions,  but,  on  the  other  hand,
onfer  resistance  to  infections.
In  light  of  the  large  number  of  evidences  correlat-
ng  HLA-B*57:01  and  abacavir-induced  HDR,  the  genetic
creening  prior  to  abacavir  treatment  is  recommended  by
ood  and  Drug  Administration  (FDA),  European  Medicines
gency  (EMA),  and  virtually  all  international  HIV  treatment
uidelines  [32,33]. Currently,  HLA-B*57:01  is  one  of  most,  if
ot  the  most,  commonly  used  pharmacogenetic  marker  in
linical  practice.
arbamazepine
tevens-Johnson  syndrome  (SJS)  and  toxic  epidermal
ecrolysis  (TEN,  also  known  as  Lyell’s  syndrome)  are
evere  mucocutaneous  reactions  characterized  by  extensive
etachment  of  the  skin.  These  skin  reactions  are  considered
o  be  variants  of  the  same  disease  and  they  are  classified
ccording  to  the  degree  of  skin  involvement  which  is  <  10%
n  SJS,  and  >  30%  in  TEN.  A  skin  detachment  of  10  to  30%  of
ody  surface  area  is  named  SJS/TEN  overlap  [38]. SJS/TEN
re  rare  diseases  with  an  incidence  of  2—6  cases/million  per
ear  but  both  are  associated  with  high  morbidity  and  mor-
ality  (5%  and  50%  mortality  for  SJS  for  TEN,  respectively)
38,39].  From  a  pathophysiological  points  of  view,  SJS/TEN
re  attributable  to  autoreactive  CD8+  cytotoxic  lympho-
ytes  that  cause  keratinocytes  death  through  the  release
f  cytotoxic  molecules,  such  as  soluble-FasL,  granzyme  B,
erforin,  granulysin  and  pro-apoptotic  cytokines  [40].  In  the
ast  majority  of  cases  SJS/TEN  are  triggered  by  drugs  and
everal  medications  are  considered  at  high  risk  of  inducing
JS/TEN  [41].
Carbamazepine  is  an  aromatic  amine  anticonvulsant
idely  employed  to  treat  epilepsy,  bipolar  disorder,  and
rigeminal  neuralgia.  Carbamazepine  is  generally  safe,  but
as  been  associated  with  maculopapular  eruption  (MPE),
rug  rash  with  eosinophilia  and  systemic  symptoms  (DRESS)
yndrome  (also  known  as  DIHS  [drug-induced  hypersensi-
ivity  syndrome]),  and  more  rarely  SJS/TEN  [42].  In  2004,
hung  et  al.  reported  a  very  strong  association  between
arbamazepine-induced  SJS/TEN  and  the  HLA-B*15:02  allele
n  Han  Chinese  patients  from  Taiwan.  They  observed  that
ll  patients  with  carbamazepine-induced  SJS/TEN  carried
he  HLA-B*15:02  allele  as  compared  to  only  3%  of  drug-
olerant  subjects  and  8.6%  of  the  general  population  [43].
urther  studies  have  replicated  this  association  in  differ-
nt  Asian  areas  including  China,  Thailand,  Malaysia,  India,









Table  1  Most  relevant  genotype-based  pharmacogenomics  relationships  between  HLA  and  drug  hypersensitivity  [29—33].
Drug  Level  of
evidence
[29]
Allele  Clinical  manifestation  Population  Risk  of  ADR  Clinical  implementation  [29,32,33]
French  National  Pharmacogenetics
network  (RNPGx)  recommendations
Abacavir  1A  HLA-B*57:01  DRESS  Mixed  population  Increased  FDA:  boxed  warning,  test
recommended,  EMA:  test  required,
PMDA:  label  information,  HCSC:
test  recommended,  CPIC:
alternative  drug  for  positive
patients,  test  recommended
DPWG:  alternative  drug  for  positive
patients,  virtually  all  HIV
Treatment  Guidelines:  test
required/recommended
PPV  =  55%,  NPV  =  100%  for  patch
test  confirmed,  NNT  to  prevent
‘‘1’’  =  32
RNPGx  reco:  essential
Acetazolamide  4  HLA-B*59:01  SJS/TEN  Asian  (Korean)  Increased  RNPGx  recommendation:  no
indication  in  routine  care
Acetaminophen  3  HLA-DQB1*02:02  SJS/TEN  Caucasian  (Italian)  Increased  RNPGx  reco:  no  indication  in
routine  care
Allopurinol  1A  HLA-B*58:01  SJS/TEN  Mixed  Population  Increased European  national  competent
authorities:  warning  (no  genotyping
recommendations),  ACR:
alternative  drug  for  HLA-B*58:01
positive  patients,  CPIC:  alternative
drug  for  HLA-B*58:01  positive
patients
HLA-B*58:01  test
PPV  =  3%,  NPV  =  100%  in  Han
Chinese,  NNT  to  prevent  ‘‘1’’  =  250
RNPGx  reco:  HLA-B*58:01
potentially  useful  namely  in  Asian
ancestry  populations  (Han  Chinese,
Thaï  and  Taiwanese)
2B  HLA-A*33:03  Drug  Hypersensitivity,
SJS/TEN
Mixed  population  Increased
3  HLA-A*02:01  SJS/TEN  Asian  Decreased
3  HLA-B*48:01  Drug  Hypersensitivity  Asian  Increased  (not
in  all  studies)
3  HLA-C*03:02  Rash  Asian  (Korean)  Increased
3  HLA-C*08:01  Drug  Hypersensitivity  Mixed  population  Increased  (not
in  all  studies)
3  HLA-DQB1*05:02  SJS/TEN  Caucasian  (Italian)  Increased
3  HLA-DR9;  HLA-DR14  MPE  Asian  Increased
3  HLA-DRB1*03:01  (in  LD
with  HLA-B*58:01  in
some  populations)
SJS/TEN  Asian  (Han  Chinese)  Increased
3  HLA-DRB1*15:02,
HLA-DRB1*13:02
SJS/TEN  Caucasian  (Italian)  Increased
Aspirin  2B  HLA-DPB1*03:01  Asthma  Mixed  population  Increased N/A
RNPGx  reco:  HLA-B*58:01:  no









Table  1 (Continued)
Drug  Level  of
evidence
[29]
Allele  Clinical  manifestation Population Risk  of  ADR Clinical  implementation  [29,32,33]
French  National  Pharmacogenetics





Pancreatitis European  Increased  N/A
RNPGx  reco:  no  indication  in
routine  care
Carbamazepine  1A  HLA-B*15:02  SJS/TEN  Mainly  Asiana Increased HLA-B*15:02
FDA:  Boxed  Warning,  test  required
(patients  with  Asian  ancestry),
European  national  competent
authorities:  warning,  test
recommended  (patients  with  Asian
ancestry),  PMDA:  label  information,
HCSC:  test  recommended,  CPNDS:
drug  contraindicated  for  positive
patients
Asian:  PPV  =  1.8%,  NPV  = 100%,  NNT
to  prevent  ‘‘1’’  =  461
HLA-A*31:01
FDA:  warning  (no  genotyping
recommendations),  European
national  competent  authorities:
warning  (no  genotyping
recommendations),  HCSC:  test
recommended,  CPNDS:  drug
contraindicated  positive  patients
Japanese:  PPV  =  12%,  NPV  =  99%,
NNT  to  prevent  ‘‘1’’  =  67
Caucasian:  PPV  =  43%,  NPV  =  92%,
NNT  to  prevent  ‘‘1’’  =  47
RNPGx  reco:  HLA-B*15:02  advisable
in  Asian  ancestry  populations  (Han
Chinese  and  Taiwanese)
2A  HLA-B*15:11  SJS/TEN  Asian  (Japanese,
Korean,  Han  Chinese)
Increased
2B  HLA-A*31:01  DRESS,  MPE,  SJS/TEN Mixed  populationa Increased
2B  HLA-B*40:01  SJS/TEN  Asian  (Han  Chinese,
Taiwanese)
Decreased
2B  HLA-C*03:02  (in  LD
with  HLA-B*58:01  in
some  populations)
SJS/TEN  Mixed  population  Increased
3  HLA-B*15:18  SJS/TEN  Asian  (Japanese)  Increased
3  HLA-B*58:01  MEP  Asian  (Han  Chinese)  Decreased
3  HLA-B*58:01  SJS/TEN  Asian  (Han  Chinese)  Increased
(decreased  in
one  study)
3  HLA-B*59:01  SJS/TEN  Asian  (Japanese)  Increased
3  HLA-B*13:01  Drug  Hypersensitivity  Caucasian,  Asian  Increased  (not
in all  studies)
3  HLA-B*46:01  SJS/TEN  Asian  Decreased
3  HLA-DRB1*03:01  MEP  Asian  (Han  Chinese)  Increased
Clozapine  3  HLA-DRB3*02:02  Agranulocytosis  Caucasian  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
Dapsone  2A  HLA-B*13:01  Drug  hypersensitivity  Asian  Increased  PPV  =  7.8%,  NPV  =  99.8%
NNT  to  prevent  ‘‘1’’  =  84
RNPGx  reco:  no  indication  in
routine  care















Table  1  (Continued)
Drug  Level  of
evidence
[29]
Allele  Clinical  manifestation  Population  Risk  of  ADR  Clinical  implementation  [29,32,33]
French  National  Pharmacogenetics
network  (RNPGx)  recommendations
Flucloxacillin  3  HLA-B*57:01  Drug-induced  liver
injury
Caucasian  Increased  PPV  =  0.12%,  NPV  =  99.99%
NNT  to  prevent  ‘‘1’’  =  13,819
RNPGx  reco:  no  indication  in
routine  care
Lamotrigine  3  HLA-B*58:01  SJS/TEN  Mixed  population  Increased N/A  RNPGx  reco:  no  indication  in
routine  care3  HLA-B*15:02  SJS/TEN  Asian  Increased  (only
found  in
meta-analyses)
Lapatinib  2B  HLA-DQA1*02:01  Drug-induced  liver
injury
Mixed  population  Increased HLA-DQA1*02:01  or
HLA-DRB1*07:01  alleles
carrier  =  FDA:  warning  (no
genotyping  recommendations),
EMA:  warning  (no  genotyping
recommendations),  HCSC:  warning
(no  genotyping  recommendations)
RNPGx  reco:  potentially  usefull
3  HLA-DRB1*07:01  Drug-induced  liver
injury
Mixed  population  Increased
Methazolamide  2A  HLA-B*59:01  SJS/TEN  Asian  (Korean,
Japanese,  Chinese)
Increased N/A
RNPGx  reco:  no  indication  in
routine  care2B  HLA-C*01:02  SJS/TEN  Asian  (Korean,
Chinese)
Increased
Nevirapine  2A  HLA-B*35:01  Drug  Hypersensitivity
(rash)
Mixed  population  Increased
(reported  to  be
depend  on  CD4
T-cells  count)
N/A
RNPGx  reco:  no  indication  in
routine  care
2B  HLA-DRB1*01:01  Drug  hypersensitivity
(hepatitis)
Mixed  population  Increased
3  HLA-B*35:01  Drug  hypersensitivity
(rash)
Asian  (Thai)  Increased
(reported  to  be
depend  on  CD4
T-cells  count)
3  HLA-DQB1*05:01  Drug  hypersensitivity
(various
manifestations)











Table  1 (Continued)
Drug  Level  of
evidence
[29]
Allele  Clinical  manifestation  Population  Risk  of  ADR  Clinical  implementation  [29,32,33]
French  National  Pharmacogenetics




3 HLA-DR11  Anaphylactoid
reactions
Spain  Increased  N/A
RNPGx  reco:  no  indication  in
routine  care
Oxcarbazepine  3  HLA-B*13:02  MEP  Asian  (Chinese) Increased N/A
RNPGx  reco:  no  indication  in
routine  care










SJS/TEN  Mixed  population Increased  N/A




3  HLA-B*38:01  Non-responder  to
therapy
Egyptian  N/A DPWG:  information  about  lower
response  in  HLA-B*44  negative
patients  (no  genotyping
recommendations)
RNPGx  reco:  no  indication  in
routine  care3  HLA-B*44:02  Sustained  response Spain  N/A
Phenobarbital 3  HLA-B*51:01  SJS/TEN  Asian  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
Phenytoin 1A  HLA-B*15:02  SJS/TEN  Asian  Increased FDA:  warning  (no  genotyping
recommendations),  CPIC:  drug
contraindicated  for  B*15:02
positive  patients
HLA-B*15:02  test:  PPV  =  33%,
NPV  =  100%
RNPGx  reco:  HLA-B*15:02  advisable
in  Asian  ancestry  populations  (Han
Chinese  and  Taiwanese)
3  HLA-B*13:01  SJS/TEN  Asian  Increased  (not
increased  in
one  study)
3  HLA-B*56:02  DRESS  Indigenous  Australian  Increased
Sulfasalazine  3  HLA-B*39:01;
HLA-B*13:01
DRESS  Asian  Increased N/A  RNPGx  reco:  no  indication  in
routine  care
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Drug  Level  of
evidence
[29]
Allele  Clinical  manifestation  Population  Risk  of  ADR  Clinical  implementation  [29,32,33]
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2A HLA-B*38:02:01  Agranulocytosis  Mixed  population  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
Ticlopidine  3  HLA-B*44:03  Hepatotoxicity  and
cholestatic
hepatotoxicity
Asian  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
Trichloroethylene  3  HLA-B*13:01  Hypersensitivity
dermatitis
Asian  (Chinese)  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
Ustekinumab  3  HLA-C*06:02  Better  response
(psoriasis)
Caucasian  N/A  N/A  RNPGx  reco:  no  indication  in
routine  care




European  Increased  Withdrawn  in  2006  following
reports  of  hepatotoxicity
Zonisamide  3  HLA-A*02:07:01  SJS/TEN  Asian  (Japanese)  Increased  N/A  RNPGx  reco:  no  indication  in
routine  care
ACR: American College of Rheumatology; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network for Drug Safety; DPWG: Dutch
Pharmacogenetics Working Group; DRESS: drug reaction with eosinophilia and systemic symptoms; EMA: European Medicines Agency; FDA: US Food and Drug Administration; HCSC: Health
Canada (Santé Canada); HDRs: hypersensitivity drug reactions; MPE: maculopapular eruption; NPV: negative predictive value; OR: odds ratio; PMDA: Pharmaceuticals and Medical Devices
Agency — Japan; PPV: positive predictive value; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis. RNPGx recommendations are categorized into 4 categories: essential,
advisable, potentially usefull and no indication in routine care.























































Pharmacogenetics  of  hypersensitivity  drug  reactions  
analyses  that  combined  data  obtain  from  different  Asian
population  all  found  odds  ratios  of  approximately  80  for
carbamazepine-induced  SJS/TEN  in  patients  carrying  the
HLA-B*15:02  allele  [54—56].  A  2011  large  prospective  study,
intended  to  evaluate  the  value  of  HLA-B*15:02  genotyp-
ing  before  carbamazepine  treatment,  demonstrated  that
SJS/TEN  did  not  develop  in  any  of  the  treated  patients
if  the  subjects  were  HLA-B*1502-negative.  Considered  an
expected  incidence  of  0.23%  based  on  historical  data,  the
genetic  screening  successfully  prevented  10  cases  of  HDR
[57].  These  results  paved  the  way  for  the  implementation
of  HLA-B*15:02  screening  before  carbamazepine  therapy
in  Asian  patients.  Nevertheless,  HLA-B*15:02  has  not  been
found  to  be  a  risk  factor  in  Caucasian  or  Japanese  popula-
tions,  probably  because  of  the  very  low  prevalence  of  this
allele  in  these  ethnic  group  (1%  or  less).  In  European  or
Japanese  recent  data  suggests  that  carbamazepine-related
HDRs,  including  SJS/TEN,  MPE,  and  DRESS,  are  associated
with  the  presence  of  the  HLA-A*31:01  allele  [54,58—61].
Interestingly,  in  Han  Chinese,  HLA-A*31:01  allele  has  been
associated  with  an  increased  risk  of  carbamazepine-induced
MPE  or  DRESS,  while  HLA-B*15:02  is  related  only  to  SJS/TEN
[27,46,54].  These  observations  suggest  that  genetic  suscep-
tibility  to  carbamazepine-related  HDRs,  at  least  in  certain
populations,  seems  to  be  phenotype-specific.  Beyond  HLA-
B*15:02  and  HLA-A*31:01,  other  HLA  alleles  have  been
associated  to  an  increased  risk  of  carbamazepine-related
HDRs  in  various  populations  (Table  1),  nevertheless  these
studies  are  limited  and  need  further  confirmation.  At  this
time,  FDA  recommends  HLA-B*15:02  genetic  testing  prior
to  a  carbamazepine  based  treatment  in  individuals  of  Asian
ethnicity  [32,33].  A  warning  has  been  added  to  the  prescrib-
ing  information  by  FDA  indicating  that  the  risks  and  benefits
of  using  carbamazepine  should  be  weighed  in  HLA-A*31:01
allele  carriers  [33].  Different  reports  put  HLA-B*15:02  in
relation  also  with  SJS/TEN  induced  by  aromatic  antiepilep-
tic  drugs,  other  than  carbamazepine,  such  as  phenytoin,
oxcarbazepine  and  lamotrigine  [7,46,54,62].  These  find-
ings  suggest  that  HLA-B*15:02  positive  patients  may  show
cross-reactivity  to  structurally  related  anticonvulsants  and
consequently  special  attention  should  be  given  when  consid-
ering  antiepileptic  treatment  for  HLA-B*1502  allele  carriers
[63].  Currently,  FDA  advise  to  avoid  phenytoin  as  alter-
native  for  carbamazepine  in  HLA-B*1502  positive  patients,
although  it  does  not  make  specific  recommendations  for
other  structurally-related  anticonvulsant  [33].
Allopurinol
Allopurinol  is  a  xanthine  oxidase  inhibitor  used  to  treat  dis-
orders  associated  with  hyperuricemia,  such  as  chronic  gout
and  tumor  lysis  syndrome.  The  most  serious  ADRs  associated
to  allopurinol  are  HDRs,  which  include  DRESS  and  SJS/TEN
and  occur  in  approximately  0.1—0.4%  of  treated  patients
[64].  Allopurinol  is  the  most  frequent  cause  of  SJS/TEN
in  Europe,  exceeding  carbamazepine  and  phenytoin,  while
in  southeast  Asia,  is  the  second  most  common  SJS/TEN-
causative  drug  after  carbamazepine  [45,65].In  2005,  a  case-controlled  study  reported  that  a  spe-
cific  HLA  allele,  HLA-B*58:01,  was  present  in  100%  of
patients  with  allopurinol-induced  HDRs  compared  to  15%






rols  [66].  Similar  results  have  been  replicated  in  other
thnic  groups:  strong  association  was  reported  in  Han
hinese,  Thais,  Japanese  and  Koreans  while  weaker  associ-
tion  was  described  in  Europeans  [67—72]. This  differences
robably  reflect  the  different  prevalence  of  HLA-B*58:01
hich  is  higher  in  Asian  populations  as  compared  to
uropeans  and/or  additional  contributing  factors  not  yet
lucidated.  However,  a  recent  meta-analysis  found  a  strong
nd  significant  association  the  HLA-B*58:01  allele  and
llopurinol-induced  SJS/TEN  (OR  96.60  and  OR  79.28  in
tudies  with  matched-control  or  population-control,  respec-
ively)  in  both  Asian  and  non-Asian  populations  [73]. In
he  light  of  the  strong  association  of  HLA-B*58:01  with
ypersensitivity  reactions  to  allopurinol  across  different
opulations,  a genetic  screening  of  patients  prior  to  initiat-
ng  allopurinol  will  be  most  likely  adopted  in  future.  To  date,
DA  and  EMA  have  not  implemented  allopurinol  labeling
nformation  for  HLA-B*58:01  testing.  The  Clinical  Pharmaco-
enetics  Implementation  Consortium  guidelines  recommend
hat  allopurinol  should  not  be  prescribed  to  patients  who  are
ositive  for  the  HLA-B*5801  allele  but  underline  that  nega-
ive  testing  does  not  exclude  the  possibility  of  developing
CARs,  especially  in  European  populations  [64].  The  2012
evised  guidelines  of  the  American  College  of  Rheumatology
lso  recommend  HLA-B*58:01  screening  prior  to  allopurinol
rescription,  especially  in  those  populations  with  high  fre-
uencies  of  the  allele,  such  as  the  Han  Chinese  or  Thais
74].
onclusion
bacavir,  carbamazepine,  and  allopurinol  are  key  examples
f  pharmacogenetics  implementation  in  routine  medical
ractice  (Table  2)  [75], but  many  other  HLA-related  HDRs
ave  been  reported  so  far  (Table  1).  However,  several
onsiderations  should  be  taken  into  account  before  such
ssociations  could  be  translated  in  cost-effective  screening
rocedures,  these  factors  have  been  recently  reviewed  by
hillips  and  Mallal  [76].  Premises  for  a successful  implemen-
ation  of  a  given  HLA  pharmacogenetic  testing  into  routine
linical  care  requires  that:  drug  toxicity  is  severe  and  per-
istent,  the  NPV  (and  ideally  also  the  PPV)  of  the  test  reach
00%,  culprit  HLA  allele  is  prevalent  inside  the  screened
opulation,  and  the  number  of  patients  needed  to  test  in
rder  to  prevent  a  case  is  low.  In  addition,  responsible  drug
hould  have  good  efficacy,  cost-effectiveness  and,  tolerabil-
ty,  in  the  absence  of  alternative  drug(s)  with  similar  positive
haracteristics.  Flucloxacillin-related  liver  toxicity  can  be
ited  as  a  paradigmatic  example,  although  strongly  associ-
ted  with  HLA-B*57:01  allele  (OR  80),  almost  14,000  patients
hould  be  tested  to  prevent  a  single  case  of  hepatotoxic-
ty,  making  this  screening  neither  cost-effective  nor  feasible
34,77].  In  view  of  this,  only  few  HLA-disease-drug  associ-
tions  reported  to  date  will  be  reasonably  translated  into
outine  clinical  practice.
Nevertheless,  clinical  value  of  pharmacogenetic  mark-
rs  is  not  only  limited  to  predict  susceptibility  to  HDR  in
re-treatment  setting  but  may  also  be  exploited  as  tests
f  exclusion,  as  has  been  proposed  for  the  re-introduction
f  lumiracoxib,  or  differential  diagnosis  tools,  as  has  been









Table  2  Main  genetic  variants  discussed  in  this  article.
Genea Namea Polymorphisma Reference
rs
Common  name
of  the  allele
Frequency  of  HLA  alleles  across










complex,  class  I,  A
*57:01  N/A  HLA-B*57:01  West  Europe:  5—10%,
Mediterranean:  1—4%,  UK:  5—10%,
Middle  East:  1—4%,  US  Caucasian:
5—10%,  US  Asia:  1—3%,  US
African-American:  2—3%,  US
Hispanic:  1—5%,  South  American
Caucasian:  5—10%,  Sub-Saharan
Africa:  <  1%,  Australia:  5—10%,
Thailand:  5—10%,  China:  <  1%,
Japan:  <  1%,  India:  5—15%
N/A  N/A
*58:01  N/A  HLA-B*58:01  West  Europe:  1—4%,
Mediterranean:  1—4%,  UK:  <  1%,
Middle  East:  5—10%,  US  Caucasian:
1—4%,  US  Asia:  5—10%,  US
African-American:  5—10%,  US
Hispanic:  1—4%,  South  American
Caucasian:  1—4%,  Sub-Saharan
Africa:  5—15%,  Australia:  1—4%,
Thailand:  5—15%,  China:  5—20%,
Japan:  <  1%,  India:  5—15%
N/A  N/A
*15:02  N/A  HLA-B*15:02  West  Europe:  <  1%,  Mediterranean:
<  1%,  UK:  <  1%,  Middle  East:  <  1%,
US  Caucasian:  <  1%,  US  Asia:
5—10%,  US  African-American:  <  1%,
US  Hispanic:  <  1%,  South  American
Caucasian:  <  1%,  Sub-Saharan
Africa:  <  1%,  Australia:  <  1%,
Thailand:  10—20%,  China:  5—20%,
Japan:  <  1%,  India:  5—15%
N/A  N/A
From a practical point of view, HLA genotyping test for drug hypersensitivity should be interpreted as follow. Since HLA expression is co-dominant, results are reported as either
‘‘positive’’ or ‘‘negative’’, with no intermediate phenotype. The absence of the tested alleles (reported as ‘‘negative’’ on a genotyping test) indicates that the patient has a very low
risk of HDR. On the opposite, ‘‘positive’’ result (heterozygote and homozygous variants) means that the drug is contraindicated due to the increased risk of drug-induced hypersensitivity
[39]. N/A: not applicable.
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to  their  pharmacological  unpredictability  and  very  low
incidence,  HDRs  are  usually  recognized  in  the  post-
marketing  phase  of  the  drug  life  cycle  leading  to  product
withdrawal  after  important  investment  has  been  made  in
research  and  development.  A  systematic  DNA  banking  during
drug  development  phase  could  allow,  if  a  HDR  occurs,  to  ret-
rospectively  research  a  susceptibility  genomic  biomarker.  In
this  context,  successful  identification  of  a  predictive  marker
could  avert  withdrawal  of  the  drug  from  the  market  by
limiting  the  use  of  the  drug  to  genetically  tolerant  sub-
jects  [79].  Last  but  not  least,  progresses  in  basic  research  on
immunological  mechanisms  involved  in  HDRs  could  improve
drug  design,  and  lay  the  groundwork  for  the  development  of
in  vitro  tests  capable  to  identify  harmful  compounds  in  pre-
clinical  phases  of  drug  development.  These  implementations
would  increase  drug  safety  by  predicting  HDRs  before  their
use  in  man,  and,  at  the  same  time,  would  greatly  reduce  the
cost  of  drug  development  [80].
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